The Health Care Fraud Strike Force, FBI, HHS Office of Inspector General, DEA, and CMS coordinated the takedown alongside parallel civil and administrative actions. CMS suspended 1,079 providers and revoked billing privileges for 1,403 others. HHS-OIG pursued over $10 billion in civil monetary penalties, while the DEA initiated 928 administrative cases to revoke controlled-substance authority. Civil settlements totaled $37.8 million across 44 defendants. The schemes targeted included telemedicine and genetic testing fraud ($1.17 billion), durable medical equipment kickbacks, allograft billing abuse exceeding $4 billion, and opioid diversion. CMS reduced Medicare's allograft payment to $127 per square centimeter in January 2026 to address fraud-driven cost increases.
Attorneys should recognize this takedown as a structural shift in federal enforcement strategy. The DOJ's new National Fraud Enforcement Division integrated criminal prosecution with asset seizure, civil remedies, administrative exclusions, and payment-policy changes—treating high-cost reimbursement categories as enterprise-risk environments. Vulnerable patient populations, including hospice and homebound patients, are now flagged as heightened-risk targets. The 455 criminal charges, combined with the unprecedented international reach and coordinated whole-of-government approach, signal intensifying accountability across health care providers and investors. Enhanced due diligence on expensive products serving patients with limited healing potential is now essential.